India's first ATM for early diagnosis of heart risk factors launched during NHF conclave

New Delhi, April 8, 2022: Amid the rising incidence of heart failure in India, IMA NDB organised National Heart Failure Conclave-2022 last week at Hotel Eros international, Nehru Place, New Delhi to discuss the evolution of revolutionary pillars of medication for heart failure and device therapy. Over 200 eminent doctors/cardiologists from Delhi/NCR attended the conclave and deliberated on different aspects of preventive heart care.

India’s first-of-its-kind Health ATM screening hPoD developed by India Health Link (IHL) for early diagnosis of heart health risk factors introduced during the National Heart Failure Conclave-2022 concluded last week. The IHLs hPod (Fitness Station/Health Kiosk/Health ATM) is a non-invasive digitally integrated PHYGITAL (Physical+Digital) ecosystem, connecting Primary, Preventive and Predictive Healthcare. Over 50 attendee doctors got tested for 22 vitals in less than 5 minutes and showed a sense of satisfaction, appreciating its handy features that deliver the test report at the spur of the moment.

Founder and CEO of India Health Link (IHL), Dr Satyender Goel says that the incidence of heart attacks in India is increasing and preventive measure in terms of the unique hPoD is in place, which is instrumental in preventive heart health care. The ‘hPod’ is a self-service ATM size health station, which is capable of screening (22) essential vital parameters including key parameters like Blood Pressure, Temperature, Body Mass Composition, Pulse, SPO2, and ECG, without any paramedic assistance. These key parameters are the leading reasons for heart failure and heart attacks. But the features of the health ATM brought by IHL have the technical acumen that indicates the upcoming metabolic disorders, which can be diagnosed and prevented early. The hPoD (Health ATM) is supposed to serve as preventive care in the long run.

Speaking during the conclave, Dr Viveka Kumar, President, IMA NDB and Senior Consultant, Cardiologist and Director at Max Heart and Vascular Institute, New Delhi threw light and said, “The power and promise of ARNI for the reduction in the heart failure hospitalization, and reduction on the severity and worsening of heart failure is immense. And there is the need for device therapy and other interventions that may reduce if timely titrated ARNI therapy is instituted.”

Dr H.K. Chopra, Chief Advisor, NHFC-2022, National Awardee, Science & Technological Communications, Past President, Cardiological Society of India, Senior Consultant Cardiologist, Medanta Moolchand, Heart Institute said, “There is a need for timely NT pro-BNP and Echocardiographic evaluation in heart failure patients as they are the cornerstone of management. The SGLT2i reduces the need for diuretics, and mechanical and surgical intervention and helps in the reversal of morphological and functional remodelling of the heart, thereby increasing survival. Short term and long-term mortality benefits are documented throughout the world about timely intervention with ARNI and SGLT2i in Heart Failure.”